26-08-2010

Addex Pharmaceuticals Ltd announced that the Phase I studies required to commence Phase II testing of ADX71149 have been satisfactorily completed. Subject to regulatory authorizations, Phase IIa studies in schizophrenia and anxiety, are scheduled to start enrolling patients in the first ...

more

30-09-2009

Johnson & Johnson and Crucell N.V. announced that Johnson & Johnson, through its subsidiary Ortho-McNeil-Janssen Pharmaceuticals, Inc., and Crucell have entered into a strategic collaboration focusing on the discovery, development and commercialization of monoclonal antibodies and vaccines ...

more

16-07-2009

Bayer Schering Pharma AG, Germany, announced that its partner, Ortho-McNeil, does not expect to submit its complete response to the U.S. Food and Drug Administration (FDA) until the fourth quarter of this year, at the earliest. “We are fully convinced of the positive risk-benefit profile of ...

more

Novel Approach Has Potential for Treatment of Multiple CNS Disorders

25-06-2009

Addex Pharmaceuticals announced that its partner Ortho-McNeil-Janssen Pharmaceuticals Inc. (OMP) has started Phase I testing of ADX71149, a metabotropic glutamate receptor 2 (mGluR2) positive allosteric modulator (PAM). This product, which has potential to treat schizophrenia, anxiety, ...

more

15-03-2007

Cellzome Inc. announced that it has received the first milestone payment for its Gamma Secretase Modulator (GSM) program in connection with the selection of a lead compound by Ortho-McNeil Pharmaceutical, Inc. under its agreement with Cellzome. Ortho-McNeil entered into a collaboration and ...

more

Patient Recruitment for Phase III Clinical Trial to Start in Studies of Oral Anticoagulant in Chronic Indications

10-11-2006

After extensive discussions with the regulatory authorities in the U.S. and Europe, Bayer and Ortho-McNeil, Inc. have determined the final design of the phase III study program for the oral anticoagulant rivaroxaban in two chronic indications: Stroke prevention in atrial fibrillation (SPAF) ...

more

Company Files Pre-Market Approval Applicaton for Cosmetic Tissue Augmentation Product

05-09-2005

Anika Therapeutics, Inc. announced that it has reached a mutual agreement with OrthoNeutrogena, a division of Ortho-McNeil Pharmaceuticals, for the termination of its development and commercialization contract for Anika's hyaluronic acid based cosmetic tissue augmentation (CTA) product, ...

more

15-08-2005

Arena Pharmaceuticals, Inc. announced that it was granted patent number 1133559, entitled "HUMAN ORPHAN G PROTEIN-COUPLED RECEPTOR RUP3," by the European Patent Office. The patent relates to certain drug screening methods utilizing the 19AJ receptor, an orphan G protein-coupled receptor, or ...

more

13-06-2005

7TM Pharma A/S announced that it has entered into an exclusive worldwide license agreement and research collaboration with Ortho-McNeil Pharmaceutical, Inc., a Johnson & Johnson company, to further develop 7TM Pharma's program on novel oral compounds for the treatment of asthma and allergic ...

more

18-01-2005

Addex Pharmaceuticals announced that it has entered an exclusive worldwide research collaboration and licence agreement with Ortho-McNeil Pharmaceutical, Inc. to discover, develop and commercialize novel compounds modulating allosterically G-Protein Coupled Receptors for the treatment of ...

more